Monoclonal Protein on Serum Protein Electrophoresis (M Component)
Monoclonal gammopathy of unknown significance (MGUS)
Low concentration of monoclonal immunoglobulins (LCMI)
Heavy chain disease
Suggested Additional Lab Testing
For multiple myeloma:
In addition to SPEP followed by immunofixation, quantitative serum immunoglobulin should be performed, because the M component must be greater than3 g/dL in the serum.
Bone marrow aspirate may be useful to show that at least 10% of the nucleated blood cells are plasma cells.
Bone marrow biopsy may be useful to show aggregates of plasma cells in focal or diffuse patterns.
CBC often reveals a normochromic normocytic anemia.
Peripheral blood smear often shows RBCs in a stacked or rouleaux formation.
For Waldenstrom macroglobulinemia:
Immunofixation to identify the M component as an IgM immunoglobulin with a quantitative IgM level greater than 3 g/dL
Serum viscosity is usually increased.
Peripheral blood smear often shows RBC aggregates in a rouleaux formation.
For heavy chain disease:
Immunofixation reveals the heavy chain as alpha, gamma, or mu.
Bone marrow examination may be informative.
Quantitative determination of the serum M component to demonstrate that an IgG or IgM monoclonal protein is less than 3.0 g/dL or an IgA monoclonal protein is less than 2.0 g/dL, or that a Bence-Jones protein is less than or equal to 1.0 g in a 24-hour urine specimen
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|